Navigation Links
Cell-death receptor links cancer susceptibility and inflammation
Date:12/27/2007

PHILADELPHIA - For over 10 years, Wafik S. El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology at the University of Pennsylvania School of Medicine, has been pursuing a cancer-targeting molecule called TRAIL and its molecular partners. TRAIL is normally produced by immune cells and curtails tumor spread by binding to a specialized receptor on a tumors surface.

However, in cancer patients who often have suppressed immunity, and for reasons we still dont understand, there isnt enough TRAIL being produced, so tumors are not suppressed, explains El-Deiry, who is also Co-Program Leader of the Radiation Biology Program for the Abramson Cancer Center at Penn.

Most recently, El-Deiry and colleagues demonstrated for the first time a link between TRAILs receptor and cancer susceptibility, as reported online December 13, 2007 in the Journal of Clinical Investigation in advance of the January 2008 print issue. Unexpectedly, they also found a connection via Trail between inflammation and cancer susceptibility.

Mice engineered without the TRAIL receptor on their cells versus healthy controls developed larger and more tumors in their livers and other organs after being challenged with a chemical carcinogen or radiation. The team also bred TRAIL receptor knock-out mice with mice genetically engineered to get B-cell lymphomas that metastasize to the liver. Their offspring displayed more liver tumors compared to controls. This is the first direct in vivo evidence that loss of the tumor death-inducing TRAIL receptor confers cancer susceptibility, says El-Deiry.

When intact, TRAIL and its receptor decrease the influx of inflammatory cells and molecules that can lead to cancer. New models of cancer have suggested a link between inflammation and cancer in the last five years, and El-Deiry is in the early stages of trying to understand this connection with respect to the TRAIL pathway.

For example, in this study, the mice without the TRAIL receptor that were irradiated developed chronic pneumonia, an inflammatory response, as well tumors, evidence pointing to the connection between cancer and inflammation via TRAIL. One benefit of this work is that it provides a new and unanticipated model implicating a TRAIL pathway deficiency in the chronic toxicity of radiation therapy, he notes. Inflammation is a common late and serious side-effect of radiation treatment in people.

El-Deiry and his team are now looking within tumor tissue for inflammatory molecules as clues to how cancer and inflammation are coupled. Our work with TRAIL and its receptor in mouse models represents a new way to look at cancer susceptibility and its potential therapy in humans as well as new ways to decrease debilitating radiation side-effects experienced by cancer patients, says El-Deiry.

Co-authors in addition to El-Deiry are Niklas Finnberg from Penn and Andres J.P. Klein-Szanto from Fox Chase Cancer Center, Philadelphia. This research was funded in part by the National Cancer Institute.

This release can be found at www.pennhealth.com/news.


'/>"/>
Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
3. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
4. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
5. Food restriction increases dopamine receptor levels in obese rats
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
8. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
9. Receptor protein appears to be key in breakdown of kidney filtration
10. Pathway links inflammation, angiogenesis and breast cancer
11. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... and instrument solutions, announces the continuation of its strategic partnership with and platinum ... in developing nations in the safe and effective management of complex spine deformity ...
(Date:4/24/2017)... ... , ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian ... Association’s annual conference, on April 23 in Orlando, FL. , “I am proud that ... of the poor and underserved in other parts of the world,” said Jonathan Linkous, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars ... rarified air of pop and film stardom.(1) Not to be left out is that ... Grins now run the gamut from being encrusted with jewels and precious metals to, ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Veteran Theresa James ... next changed her life forever. , In “Healing Tears,” James depicts every parent’s worst ... of my attorney, I began journaling conversations and situations throughout my divorce,” James said. ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... My T ... announced its products are now available for purchase on RevNutrition.com, a popular website specializing ... tea first produced and popularized in ancient India and Siam. It spread across Asia ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology: